Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 11, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (Brca1, Brca2, Pik3ca, Ki-67, Ret, Braf, Esr1, Ntrk)PayerPolicy · CAPBLUE-MP-2.393 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genotyping for 9p21 Single Nucleotide Polymorphism to Predict Risk of Cardiovascular Disease and AneurysmPayerPolicy · CAPBLUE-MP-2.311 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genotype-Guided Warfarin DosingPayerPolicy · CAPBLUE-MP-2.306 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genotype-Guided Tamoxifen TreatmentPayerPolicy · CAPBLUE-MP-2.307 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing of CADASIL SyndromePayerPolicy · CAPBLUE-MP-2.247 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for the Diagnosis of Inherited Peripheral NeuropathiesPayerPolicy · CAPBLUE-MP-2.355 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Predisposition to Inherited Hypertrophic CardiomyopathyPayerPolicy · CAPBLUE-MP-2.248 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Pathogenic FMR1 Variants (Including Fragile X Syndrome)PayerPolicy · CAPBLUE-MP-2.276 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for PTEN Hamartoma Tumor SyndromePayerPolicy · CAPBLUE-MP-2.255 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for NeurofibromatosisPayerPolicy · CAPBLUE-MP-2.358 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Mitochondrial DisordersPayerPolicy · CAPBLUE-MP-2.273 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related DisordersPayerPolicy · CAPBLUE-MP-2.331 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Macular DegenerationPayerPolicy · CAPBLUE-MP-2.260 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Lynch Syndrome and Inherited Colon Cancer SyndromesPayerPolicy · CAPBLUE-MP-5.013 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin TreatmentPayerPolicy · CAPBLUE-MP-2.310 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Limb Girdle Muscular DystrophiesPayerPolicy · CAPBLUE-MP-2.332 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Li-Fraumeni SyndromePayerPolicy · CAPBLUE-MP-2.274 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Inherited ThrombophiliaPayerPolicy · CAPBLUE-MP-2.253 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Idiopathic Dilated CardiomyopathyPayerPolicy · CAPBLUE-MP-2.328 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Heterozygous Familial HypercholesterolemiaPayerPolicy · CAPBLUE-MP-2.363 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Hereditary PancreatitisPayerPolicy · CAPBLUE-MP-2.318 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Hereditary HemochromatosisPayerPolicy · CAPBLUE-MP-2.312 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Hearing LossPayerPolicy · CAPBLUE-MP-2.319 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Helicobacter Pylori TreatmentPayerPolicy · CAPBLUE-MP-2.308 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Fanconi AnemiaPayerPolicy · CAPBLUE-MP-2.362 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Familial Cutaneous Malignant MelanomaPayerPolicy · CAPBLUE-MP-2.246 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Facioscpulohumeral Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.321 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-2.357 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for EpilepsyPayerPolicy · CAPBLUE-MP-2.262 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Duchenne and Becker Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.257 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Diagnosis and Management of Mental Health ConditionsPayerPolicy · CAPBLUE-MP-2.264 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for DD, ID, Autism Spectrum Disorder and CAPayerPolicy · CAPBLUE-MP-2.242 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Cardiac Ion ChannelopathiesPayerPolicy · CAPBLUE-MP-2.233 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for CHARGE SyndromePayerPolicy · CAPBLUE-MP-2.322 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Alzheimer Disease (Formerly Diagnostic Testing and Risk Assessment for Alzheimer Disease)PayerPolicy · CAPBLUE-MP-2.050 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Alpha-1 Antitrypsin DeficiencyPayerPolicy · CAPBLUE-MP-2.251 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Testing for Alpha ThalassemiaPayerPolicy · CAPBLUE-MP-2.320 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic Cancer Susceptibility Panels Using Next Generational SequencingPayerPolicy · CAPBLUE-MP-2.325 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate CancerPayerPolicy · CAPBLUE-MP-2.280 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | General Approach to Genetic TestingPayerPolicy · CAPBLUE-MP-2.326 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | General Approach to Evaluating the Utility of Genetic PanelsPayerPolicy · CAPBLUE-MP-2.323 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gene Expression Profiling for Uveal MelanomaPayerPolicy · CAPBLUE-MP-2.360 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gene Expression Profiling for Cutaneous MelanomaPayerPolicy · CAPBLUE-MP-2.396 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gene Expression Profiling, Protein Biomarkers, and Multimodal Artificial Intelligence for Prostate Cancer ManagementPayerPolicy · CAPBLUE-MP-2.263 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gene Expression Profile Testing and Circulating Tumor DNA testing for Predicting Recurrence in Colon CancerPayerPolicy · CAPBLUE-MP-2.315 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gene Expression Based Assays for Cancers of Unknown PrimaryPayerPolicy · CAPBLUE-MP-2.245 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gender Affirming SurgeryPayerPolicy · CAPBLUE-MP-1.144 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gastric Electrical StimulationPayerPolicy · CAPBLUE-MP-2.069 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Gas Permeable Scleral Contact Lens and Therapeutic Soft Contact LensPayerPolicy · CAPBLUE-MP-6.031 | Metadata changed |
|---|
| May 11, 2026 | Capital Blue Cross | Ganglion Impar BlockPayerPolicy · CAPBLUE-MP-2.378 | Metadata changed |
|---|